Relative quantification of glycosaminoglycan-induced upregulation of TFPI-mRNA expression in vitro

Thrombosis Research

Volumn 119, Issue 6, 2007, Pages 785-791

  Thyzel, Elmar ^a   Kohli, Sharmila ^a   Siegling, Sabine ^a   Prante, Christian ^a   Kleesiek, Knut ^a   Götting, Christian ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Endothelial cells; Glycosaminoglycans; Heparin; Real time PCR; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

CHONDROITIN 6 SULFATE; COMPLEMENTARY DNA; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; PROTAMINE; RNA; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CELL CULTURE; CELL STIMULATION; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; GENE ISOLATION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; PRIORITY JOURNAL; UPREGULATION;

CELL LINE; CELL PROLIFERATION; CHONDROITIN SULFATES; CHONDROSARCOMA; ENDOTHELIAL CELLS; GLYCOSAMINOGLYCANS; HEPARIN; HEPARITIN SULFATE; HUMANS; LIPOPROTEINS; RNA, MESSENGER; UP-REGULATION;

EID: 33947305784     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.06.012     Document Type: Article

References (24)

1. Brinkmann T., Schmidt M., Prohaska W., and Kleesiek K. Tissue factor pathway inhibitor(TFPI): biochemistry, genetics, and implications for thrombophilia. J Lab Med 25 (2001) 269-276
2. Bajaj M.S., Birktoft J.J., Steer S.A., and Bajaj S.P. Structure and biology of tissue factor pathway inhibitor (review). Thromb Haemost 86 (2001) 959-972
3. Broze Jr. G.J. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 29 (1992) 159-169
4. Broze Jr. G.J., Warren L.A., Novotny W.F., Higuchi D., Girard J.J., and Miletich J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71 (1988) 335-343
5. Rao L.W.M., and Rappaport S.I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69 (1987) 645-651
6. Mast A.E., Acharya N., Malecha M.J., Hall C.L., and Dietzen D.J. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol 22 (2002) 2099-2104
7. Osterud B., Bajaj M.S., and Bajaj S.P. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 73 (1995) 873-875
8. Brinkmann T., Kähnert H., Prohaska W., Nordfang O., and Kleesiek K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 32 (1994) 313-317
9. Thyzel E., Siegling S., Götting C., Tinneberg H.R., Brinkmann T., and Kleesiek K. Quantification of tissue factor pathway inhibitor in human seminal plasma and human follicular fluid. Thromb Res 109 (2003) 329-332
10. Lesnik P., Vonica A., Guerin M., Moreau M., and Chapman M.J. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL with Lp(a). Arteroscler Thromb 13 (1993) 1066-1075
11. Sandset P.M., Abilgaard U., and Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50 (1988) 803-813
12. Valentin S., Ostergaard P., Kristensen H., and Nordfang O. Synergism between full length TFPI and heparin. Evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coagul Fibrinolysis 3 (1992) 221-222
13. Hansen J.B., Sandset P.M., Huseby K.R., Huseby N.E., and Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in men. Thromb Haemost 76 (1996) 703-709
14. Comper W.D. Heparin and related polysaccharides vol. 7 (1981), Gordon Breach, New York, NY
15. Capila I., and Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed Engl 41 (2002) 390-412
16. Munoz E.M., and Linhardt R.J. Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol 24 (2004) 1549-1557
17. Lindahl U., and Kjellen L. Heparin or heparan sulfate-What is the difference?. Thromb Haemost 66 (1991) 44-48
18. Hull R.D., Raskob G.E., Hirsch J., Jay R.M., Leclerc R.J., Geerts W.H., et al. Continuous intravenous heparin compared with intermittend subcutaneous heparin in the initial treatment proximal-vein thrombosis. N Engl J Med 315 (1986) 1109-1114
19. Neri Serneri G.G., Gensini G.F., Poggesi L., Trotta F., Modesti P.A., Boddi M., et al. Effect of heparin, aspirin, or alterplase in reduction of myocardial ischemia in refractory unstable angina. Lancet 335 (1990) 615-618
20. Hansen J.B., Sandset P.M., Huseby K.R., Huseby N.E., Bendz B., Ostergaard P., et al. Differential effect of unfractionated and low-molecular-weight heparin on intravascular tissue factor pathway inhibitor (TFPI): evidence for a difference in antithrombotic action. Br J Haematol 101 (1998) 638-646
21. Hansen J.B., Svensson B., Olsen R., et al. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 83 (2000) 937
22. Lupu C., Poulsen E., Roquefeuil S., Westmucket A.D., Kakkar V.V., and Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 19 (1999) 2251-2262
23. Zhang J., Piro O., Lu L., and Broze Jr. G.J. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 108 (2003) 623-627
24. Piro O., and Broze Jr. G.J. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation 110 (2004) 3567-3572